Scalper1 News
Specialty drugmaker Mallinckrodt early Wednesday beat analysts’ expectations handily with its fiscal Q4 report, but the stock fell 3.2% after the company put off providing hoped-for guidance in the wake of a Food and Drug Administration decision that hits one of its best-selling drugs. For its fiscal fourth quarter, which ended Sept. 26, Mallinckrodt (MNK) made $1.68 a share excluding one-time items, up 71% from the year-earlier quarter and 27 Scalper1 News
Scalper1 News